MedDataX Logo

Antiviral Activity of AZD7295 in HCV Carriers

NCT ID: NCT00781976

Last Updated: 2010-03-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PK, safety study of AZD7295 in HCV carriers

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

matched placebo

2

Group Type ACTIVE_COMPARATOR

AZD7295

Intervention Type DRUG

700mg per day maximum

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD7295

700mg per day maximum

Intervention Type DRUG

Placebo

matched placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HCV carrier

Exclusion Criteria

* concurrent medications
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Arrow Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Arrow Therapeutics

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ed Gane

Role: PRINCIPAL_INVESTIGATOR

Auckland Clinical Services

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Prof Ed Gane

Auckland, , New Zealand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

New Zealand

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HCV689-102

Identifier Type: -

Identifier Source: org_study_id